Literature DB >> 10322351

Leishmania-HIV interaction: immunopathogenic mechanisms.

D Wolday1, N Berhe, H Akuffo, S Britton.   

Abstract

Both Leishmania and the human immunodeficiency virus (HIV) can infect and multiply in macrophages, and both can dysregulate the immune system. Recent studies indicate that Leishmania can induce the activation of HIV in latently infected monocytic and T cells. Moreover, HIV can enhance intracellular growth of Leishmania in macrophages. Here, Dawit Wolday and colleagues examine the mechanisms that might be involved in the immunopathogenesis of Leishmania- HIV co-infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10322351     DOI: 10.1016/s0169-4758(99)01431-3

Source DB:  PubMed          Journal:  Parasitol Today        ISSN: 0169-4758


  25 in total

Review 1.  Partners in crime: co-infections in the developing world.

Authors:  A Pennycook; P Openshaw; T Hussell
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

2.  Inhibition of HIV-1-mediated syncytium formation and virus replication by the lipophosphoglycan from Leishmania donovani is due to an effect on early events in the virus life cycle.

Authors:  N Genois; B Barbeau; M Olivier; M J Tremblay
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

3.  In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensis.

Authors:  Jan Carlo Delorenzi; Leonardo Freire-de-Lima; Cerli R Gattass; Deise de Andrade Costa; Liwen He; Martin E Kuehne; Elvira M B Saraiva
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

4.  Th1/Th2 cytokine profile in patients coinfected with HIV and Leishmania in Brazil.

Authors:  Maria Zilma Andrade Rodrigues; Maria Fernanda Rios Grassi; Sanjay Mehta; Xing-Quan Zhang; Luana Leandro Gois; Robert T Schooley; Roberto Badaro
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

5.  Elevated levels of soluble non-classical major histocompatibility class I molecule human leucocyte antigen (HLA)-G in the blood of HIV-infected patients with or without visceral leishmaniasis.

Authors:  L Donaghy; F Gros; L Amiot; C Mary; A Maillard; C Guiguen; J-P Gangneux
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

Review 6.  Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies.

Authors:  Ifeoma Okwor; Jude Uzonna
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 7.  Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Paromomycin: uptake and resistance in Leishmania donovani.

Authors:  Anupam Jhingran; Bhavna Chawla; Shailendra Saxena; Michael Peter Barrett; Rentala Madhubala
Journal:  Mol Biochem Parasitol       Date:  2008-12-25       Impact factor: 1.759

9.  Immunological perspectives of leishmaniasis.

Authors:  Susanne Nylén; Shalini Gautam
Journal:  J Glob Infect Dis       Date:  2010-05

Review 10.  Drought, smallpox, and emergence of Leishmania braziliensis in northeastern Brazil.

Authors:  Anastácio Q Sousa; Richard Pearson
Journal:  Emerg Infect Dis       Date:  2009-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.